Recent Analysts’ Ratings Updates for Xenon Pharmaceuticals (XENE)

A number of research firms have changed their ratings and price targets for Xenon Pharmaceuticals (NASDAQ: XENE):

• 5/12/2026 – Xenon Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $77.00 to $80.00. They now have an “overweight” rating on the stock.
• 5/10/2026 – Xenon Pharmaceuticals had its “overweight” rating reaffirmed by Wells Fargo & Company. They now have a $69.00 price target on the stock.
• 5/8/2026 – Xenon Pharmaceuticals had its price target raised by Royal Bank Of Canada from $80.00 to $82.00. They now have an “outperform” rating on the stock.
• 5/8/2026 – Xenon Pharmaceuticals had its price target lowered by Needham & Company LLC from $80.00 to $78.00. They now have a “buy” rating on the stock.
• 4/8/2026 – Xenon Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/16/2026 – Xenon Pharmaceuticals had its price target lowered by Wedbush from $64.00 to $63.00. They now have an “outperform” rating on the stock.

Insider Activity

In other news, CEO Ian Mortimer sold 270,000 shares of the business’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $60.33, for a total transaction of $16,289,100.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares of the company’s stock, valued at approximately $361,980. The trade was a 97.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Christopher John Kenney sold 2,771 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total transaction of $166,564.81. Following the transaction, the insider directly owned 4,729 shares of the company’s stock, valued at approximately $284,260.19. This trade represents a 36.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 296,707 shares of company stock valued at $17,845,365. 4.07% of the stock is currently owned by company insiders.

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.